- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Patent holdings for IPC class A61P 3/10
Total number of patents in this class: 12545
10-year publication summary
521
|
471
|
421
|
635
|
901
|
856
|
1002
|
1002
|
853
|
239
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Eli Lilly and Company | 3645 |
175 |
Boehringer Ingelheim International GmbH | 4629 |
172 |
Takeda Pharmaceutical Company Limited | 2961 |
153 |
Janssen Pharmaceutica N.V. | 3839 |
131 |
Novo Nordisk A/S | 2324 |
126 |
F. Hoffmann-La Roche AG | 7958 |
116 |
Daiichi Sankyo Company, Limited | 1829 |
106 |
Novartis AG | 11238 |
86 |
Shionogi & Co., Ltd. | 914 |
82 |
Sanofi | 3836 |
77 |
Pfizer Inc. | 3322 |
76 |
Sanofi-Aventis Deutschland GmbH | 2738 |
75 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 762 |
72 |
Société des Produits Nestlé S.A. | 9672 |
66 |
Merck Sharp & Dohme LLC | 3689 |
64 |
The Regents of the University of California | 18943 |
63 |
AstraZeneca AB | 3042 |
62 |
Sunshine Lake Pharma Co., Ltd. | 542 |
59 |
Bristol-myers Squibb Company | 5080 |
58 |
Astellas Pharma Inc. | 1145 |
57 |
Other owners | 10669 |